DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
January 09 2019 - 5:00PM
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) (TSX-V: DMA), a clinical
stage biopharmaceutical company, announced today that it has
applied to voluntarily delist its voting common shares from the TSX
Venture Exchange.
The Company’s common shares are expected to be
delisted from the TSX-V at the close of business on January 18,
2019, being approximately 10 days from today's date.
DiaMedica’s shares will continue to be listed for trading on The
Nasdaq Capital Market (“Nasdaq”) under the trading symbol
“DMAC.” The Company believes that the continued listing of
its common shares on the Nasdaq will provide its Canadian
shareholders with a sufficiently liquid market and further, that
the financial and administrative costs associated with maintaining
a dual listing are not justified.
About DiaMedica
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company focused on developing novel treatments
for neurological and kidney diseases. DiaMedica’s shares are listed
on The Nasdaq Capital Market under the trading symbol “DMAC.”
Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.
IR Contact:Paul Papi Vice
President of Business Development 2 Carlson Parkway, Suite 260
Minneapolis, MN 55447 (617) 899-5941 info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024